Europe Neurology Clinical Trials Market Size & Outlook
Europe neurology clinical trials market, 2018-2030 (US$M)
Related Markets
Europe neurology clinical trials market highlights
- The Europe neurology clinical trials market generated a revenue of USD 1,886.6 million in 2023.
- The market is expected to grow at a CAGR of 5.6% from 2024 to 2030.
- In terms of segment, phase iii was the largest revenue generating phase in 2023.
- Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
- Country-wise, Denmark is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 1,886.6 million |
| Market revenue in 2030 | USD 2,770.2 million |
| Growth rate | 5.6% (CAGR from 2023 to 2030) |
| Largest segment | Phase iii |
| Fastest growing segment | Phase I |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
Other key industry trends
- In terms of revenue, Europe region accounted for 34.2% of the global neurology clinical trials market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,046.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Neurology Clinical Trials Market Scope
Neurology Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe neurology clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 45.19% in 2023. Horizon Databook has segmented the Europe neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Countries, such as Germany and the UK, have a large patient pool and advanced medical expertise. The doctors advocate for these trials, thus increasing patient recruitment and benefiting research & patients. The legal aspects are in a developing stage in Germany but are fully evolved in the UK and France.
The regulations are formulated to ensure safety, rights, and proper reimbursement of volunteers. With clearer protocols and increased funding, Europe is expected to be a promising region for clinical trials. Various factors such as greater access to a treatment-naïve patient pool, higher concentration of patients near sites, and close relationships between doctors & patients are expected to drive the growth of neurology clinical trials market in Europe.
Reasons to subscribe to Europe neurology clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe neurology clinical trials market databook
-
Our clientele includes a mix of neurology clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe neurology clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into Europe neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe neurology clinical trials market size, by country, 2018-2030 (US$M)
Europe Neurology Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
